{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:41:47Z","timestamp":1780641707749,"version":"3.54.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Australian Alumni Grants Fund","award":["SGF-R2-00166"],"award-info":[{"award-number":["SGF-R2-00166"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Drug-resistant falciparum malaria is an increasing public health burden. This study examined the magnitude of <jats:italic>Plasmodium falciparum<\/jats:italic> infection and the patterns and predictors of treatment failure in Vietnam.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Medical records of all 443 patients with malaria infection admitted to the Hospital for Tropical Diseases between January 2015 and December 2018 were used to extract information on demographics, risk factors, symptoms, laboratory tests, treatment, and outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>More than half (59.8%, 265\/443, CI 55.1\u201364.4%) of patients acquired <jats:italic>Plasmodium falciparum<\/jats:italic> infection of whom 21.9% (58\/265, CI 17.1\u201327.4%) had severe malaria, while 7.2% (19\/265, CI 4.6\u201310.9%) and 19.2% (51\/265, CI 14.7\u201324.5%) developed early treatment failure (ETF) and late treatment failure (LTF) respectively. Among 58 patients with severe malaria, 14 (24.1%) acquired infection in regions where artemisinin resistance has been documented including Binh Phuoc (11 patients), Dak Nong (2 patients) and Gia Lai (1 patient). Under treatment with intravenous artesunate, the median (IQR) parasite half-life of 11 patients coming from Binh Phuoc was 3\u00a0h (2.3 to 8.3\u00a0h), two patients coming from Dak Nong was 2.8 and 5.7\u00a0h, and a patient coming from Gia Lai was 6.5\u00a0h. Most patients (98.5%, 261\/265) recovered completely. Four patients with severe malaria died. Severe malaria was statistically associated with receiving treatment at previous hospitals (P\u2009&lt;\u20090.001), hepatomegaly (P\u2009&lt;\u20090.001) and number of inpatient days (P\u2009&lt;\u20090.001). Having severe malaria was a predictor of ETF (AOR 6.96, CI 2.55\u201319.02, P\u2009&lt;\u20090.001). No predictor of LTF was identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>Plasmodium falciparum<\/jats:italic> remains the prevalent malaria parasite. Despite low mortality rate, severe malaria is not rare and is a significant predictor of ETF. To reduce the risk for ETF, studies are needed to examine the effectiveness of combination therapy including parenteral artesunate and a parenteral partner drug for severe malaria. The study alerts the possibility of drug-resistant malaria in Africa and other areas in Vietnam, which are known as non-endemic areas of anti-malarial drug resistance. A more comprehensive study using molecular technique in these regions is required to completely understand the magnitude of drug-resistant malaria and to design appropriate control strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03720-3","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T07:03:22Z","timestamp":1619679802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Predictors of treatment failures of plasmodium falciparum malaria in Vietnam: a 4-year single\u2010centre retrospective study"],"prefix":"10.1186","volume":"20","author":[{"given":"Minh Cuong","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oanh Kieu Nguyet","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phong Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Vinh Chau","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-1685","authenticated-orcid":false,"given":"Phu Hoan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"3720_CR1","unstructured":"WHO. Malaria. Geneva WH Organization, 2019.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria. Accessed 29 July 2019"},{"key":"3720_CR2","doi-asserted-by":"publisher","first-page":"ofy169-ofy","DOI":"10.1093\/ofid\/ofy169","volume":"6","author":"V Orish","year":"2019","unstructured":"Orish V, Afutu L, Ayodele O, Likaj L, Marinkovic A, Sanyaolu A. A 4-day incubation period of Plasmodium falciparum infection in a nonimmune patient in Ghana: a case report. Open Forum Infect Dis. 2019;6:ofy169-ofy.","journal-title":"Open Forum Infect Dis"},{"key":"3720_CR3","doi-asserted-by":"publisher","first-page":"e0004434","DOI":"10.1371\/journal.pntd.0004434","volume":"10","author":"NV Hong","year":"2016","unstructured":"Hong NV, Delgado-Ratto C, Thanh PV, Van den Eede P, Guetens P, Binh NT, et al. Population genetics of Plasmodium vivax in four rural communities in Central Vietnam. PLoS Neglect Trop Dis. 2016;10:e0004434.","journal-title":"PLoS Neglect Trop Dis"},{"key":"3720_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12936-018-2372-8","volume":"17","author":"SM Goldlust","year":"2018","unstructured":"Goldlust SM, Thuan PD, Giang DDH, Thang ND, Thwaites GE, Farrar J, et al. The decline of malaria in Vietnam, 1991\u20132014. Malar J. 2018;17:226.","journal-title":"Malar J"},{"key":"3720_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-017-1680-8","volume":"16","author":"NV Thanh","year":"2017","unstructured":"Thanh NV, Thuy-Nhien N, Tuyen NTK, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin\u2013piperaquine in the south of Vietnam. Malar J. 2017;16:27.","journal-title":"Malar J"},{"key":"3720_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(03)15163-X","volume":"363","author":"TH Tran","year":"2004","unstructured":"Tran TH, Dolecek C, Pham PM, Nguyen TD, Nguyen TT, Le HT, et al. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet. 2004;363:18\u201322.","journal-title":"Lancet"},{"key":"3720_CR7","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva, World Health Organization, 2015. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241549127\/en\/. Accessed 15 Aug 2019."},{"key":"3720_CR8","unstructured":"Vietnam Ministry of Health. [Guideline for diagnosis and treatment of malaria](in Vietnamese). Hanoi, 2007 https:\/\/vanbanphapluat.co\/quyet-dinh-339-qd-byt-huong-dan-chuan-doan-dieu-tri-benh-sot-ret. Accessed 14 Oct 2019"},{"key":"3720_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1473-3099(17)30048-8","volume":"17","author":"M Imwong","year":"2017","unstructured":"Imwong M, Suwannasin K, Kunasol C, Sutawong K, Mayxay M, Rekol H, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis. 2017;17:491\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3720_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3720_CR11","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(19)30394-9","volume":"19","author":"D Menard","year":"2019","unstructured":"Menard D, Fidock DA. Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia. Lancet Infect Dis. 2019;19:916\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3720_CR12","unstructured":"National Institute of Malariology, Parasitology and Entomology. Guideline for the use of Pyramax in treating patients with malaria infection. Hanoi, 2019. http:\/\/nimpe.vn\/userfiles\/file\/Pyramax\/h%C6\u2009%B0%E1%BB%9Bng%20d%E1%BA%ABn.pdf. Accessed 26 Feb 2020"},{"key":"3720_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12936-018-2185-9","volume":"17","author":"C Nsanzabana","year":"2018","unstructured":"Nsanzabana C, Djalle D, Gu\u00e9rin PJ, M\u00e9nard D, Gonz\u00e1lez IJ. Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape. Malar J. 2018;17:75.","journal-title":"Malar J"},{"key":"3720_CR14","doi-asserted-by":"publisher","first-page":"7049","DOI":"10.1128\/AAC.02746-14","volume":"58","author":"K Thriemer","year":"2014","unstructured":"Thriemer K, Hong NV, Rosanas-Urgell A, Phuc BQ, Ha DM, Pockele E, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014;58:7049\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"3720_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1475-2875-10-122","volume":"10","author":"P Brasil","year":"2011","unstructured":"Brasil P, de Pina Costa A, Pedro RS, da Silveira Bressan C, da Silva S, Tauil PL, et al. Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. Malar J. 2011;10:122.","journal-title":"Malar J"},{"key":"3720_CR16","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization, 2009. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241597531\/en\/. Accessed 5 Aug 2019."},{"key":"3720_CR17","unstructured":"Vietnam Ministry of Health. [Guideline for diagnosis and treatment of malaria 2013] (in Vietnamese). Hanoi, 2013. https:\/\/thuvienphapluat.vn\/van-ban\/the-thao-y-te\/Quyet-dinh-3232-QD-BYT-2013-huong-dan-chan-doan-dieu-tri-benh-Sot-ret-207776.aspx. Accessed 26 Feb 2020."},{"key":"3720_CR18","unstructured":"Vietnam Ministry of Health. [Guideline for diagnosis and treatment of malaria 2016] (in Vietnamese). Hanoi. 2016. https:\/\/thuvienphapluat.vn\/van-ban\/The-thao-Y-te\/Quyet-dinh-4845-QD-BYT-Huong-dan-chan-doan-dieu-tri-benh-Sot-ret-2016-321533.aspx. Accessed 5 Aug 2019."},{"key":"3720_CR19","unstructured":"WHO. Antimalarial drug efficacy and drug resistance. Geneva, World Health Organization, 2018.https:\/\/www.who.int\/malaria\/areas\/treatment\/drug_efficacy\/en\/. Accessed 26 Feb 2020."},{"key":"3720_CR20","unstructured":"Huynh HQ. [An update on drug-resistant Plasmodium falciparum malaria in Vietnam and worldwide](in Vietnamese). QuyNhon, Vietnam, 2017. http:\/\/www.impe-qn.org.vn\/impe-qn\/vn\/portal\/InfoDetail.jsp?area=58&cat=1067&ID=11105. Accessed 11 Aug 2019."},{"key":"3720_CR21","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/0140-6736(90)92998-W","volume":"336","author":"HV Thien","year":"1990","unstructured":"Thien HV, Chien VT, Anh TK. Severe malaria in a provincial hospital in Vietnam. Lancet. 1990;336:1316.","journal-title":"Lancet"},{"key":"3720_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1756-3305-7-265","volume":"7","author":"NP Kar","year":"2014","unstructured":"Kar NP, Kumar A, Singh OP, Carlton JM, Nanda N. A review of malaria transmission dynamics in forest ecosystems. Parasit Vectors. 2014;7:265.","journal-title":"Parasit Vectors"},{"key":"3720_CR23","first-page":"33","volume":"76","author":"SW Lindsay","year":"1998","unstructured":"Lindsay SW, Martens WJ. Malaria in the African highlands: past, present and future. Bull World Health Organ. 1998;76:33\u201345.","journal-title":"Bull World Health Organ"},{"key":"3720_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1475-9276-11-63","volume":"11","author":"TC Bui","year":"2012","unstructured":"Bui TC, Markham CM, Ross MW, Williams ML, Beasley RP, Tran LTH, et al. Dimensions of gender relations and reproductive health inequity perceived by female undergraduate students in the Mekong Delta of Vietnam: a qualitative exploration. Int J Equity Health. 2012;11:63.","journal-title":"Int J Equity Health"},{"key":"3720_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12936-015-0601-y","volume":"14","author":"PV Thanh","year":"2015","unstructured":"Thanh PV, Van Hong N, Van Van N, Van Malderen C, Obsomer V, Rosanas-Urgell A, et al. Epidemiology of forest malaria in Central Vietnam: the hidden parasite reservoir. Malar J. 2015;14:86.","journal-title":"Malar J"},{"key":"3720_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1423-0410.2006.00733.x","volume":"90","author":"AD Kitchen","year":"2006","unstructured":"Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang. 2006;90:77\u201384.","journal-title":"Vox Sang"},{"key":"3720_CR27","doi-asserted-by":"publisher","first-page":"e240-2","DOI":"10.1016\/j.ijid.2009.04.020","volume":"14","author":"SM Alavi","year":"2010","unstructured":"Alavi SM, Alavi L, Jaafari F. Outbreak investigation of needle sharing-induced malaria, Ahvaz, Iran. Int J Infect Dis. 2010;14:e240-2.","journal-title":"Int J Infect Dis"},{"key":"3720_CR28","first-page":"328","volume":"146","author":"SJ Rogerson","year":"2017","unstructured":"Rogerson SJ. Management of malaria in pregnancy. Indian J Med Res. 2017;146:328\u201333.","journal-title":"Indian J Med Res"},{"key":"3720_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1475-2875-13-32","volume":"13","author":"MK Muhindo","year":"2014","unstructured":"Muhindo MK, Kakuru A, Jagannathan P, Talisuna A, Osilo E, Orukan F, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J. 2014;13:32.","journal-title":"Malar J"},{"issue":"Suppl 1","key":"3720_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0035-9203(00)90300-6","volume":"94","author":"World Health Organization","year":"2000","unstructured":"World Health Organization. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):1\u201390.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3720_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/1475-2875-13-370","volume":"13","author":"K Saravu","year":"2014","unstructured":"Saravu K, Rishikesh K, Kamath A. Determinants of mortality, intensive care requirement and prolonged hospitalization in malaria - a tertiary care hospital based cohort study from South-Western India. Malar J. 2014;13:370.","journal-title":"Malar J"},{"key":"3720_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1590\/S0103-507X2011000300015","volume":"23","author":"AP Gomes","year":"2011","unstructured":"Gomes AP, Vitorino RR, Costa AdP. Mendon\u00e7a EGd, Oliveira MGdA, Siqueira-Batista R. Mal\u00e1ria grave por Plasmodium falciparum. Rev Bras Ter Intensiva. 2011;23:358\u201369.","journal-title":"Rev Bras Ter Intensiva"},{"key":"3720_CR33","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1046\/j.1469-0691.2003.00640.x","volume":"9","author":"T H\u00e4nscheid","year":"2003","unstructured":"H\u00e4nscheid T. Current strategies to avoid misdiagnosis of malaria. Clin Microbiol Infect. 2003;9:497\u2013504.","journal-title":"Clin Microbiol Infect"},{"key":"3720_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/jgf2.149","volume":"19","author":"R Hase","year":"2017","unstructured":"Hase R. Diagnostic delay for imported malaria: a case of Plasmodium falciparum malaria misdiagnosed as common cold. J Gen Fam Med. 2017;19:27\u20139.","journal-title":"J Gen Fam Med"},{"key":"3720_CR35","doi-asserted-by":"publisher","first-page":"e00544","DOI":"10.1016\/j.idcr.2019.e00544","volume":"17","author":"F Al Farsi","year":"2019","unstructured":"Al Farsi F, Chandwani J, Mahdi AS, Petersen E. Severe imported malaria in an intensive care unit: a case series. IDCases. 2019;17:e00544.","journal-title":"IDCases"},{"key":"3720_CR36","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12936-015-0678-3","volume":"14","author":"M Ar\u00e9valo-Herrera","year":"2015","unstructured":"Ar\u00e9valo-Herrera M, Lopez-Perez M, Medina L, Moreno A, Gutierrez JB, Herrera S. Clinical profile of Plasmodium falciparum and Plasmodium vivax infections in low and unstable malaria transmission settings of Colombia. Malar J. 2015;14:154.","journal-title":"Malar J"},{"key":"3720_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3347\/kjp.2014.52.6.621","volume":"52","author":"U-e Asma","year":"2014","unstructured":"Asma U-e, Taufiq F, Khan W. Prevalence and clinical manifestations of malaria in Aligarh, India. Korean J Parasitol. 2014;52:621\u20139.","journal-title":"Korean J Parasitol"},{"key":"3720_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4269\/ajtmh.17-0754","volume":"98","author":"J Woodford","year":"2018","unstructured":"Woodford J, Shanks GD, Griffin P, Chalon S, McCarthy JS. The dynamics of liver function test abnormalities after malaria infection: a retrospective observational study. Am J Trop Med Hyg. 2018;98:1113\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"3720_CR39","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3346\/jkms.2016.31.9.1499","volume":"31","author":"IH Choi","year":"2016","unstructured":"Choi IH, Hwang PH, Choi SI, Lee DY, Kim MS. Delayed diagnosis of falciparum malaria with acute kidney injury. J Korean Med Sci. 2016;31:1499\u2013502.","journal-title":"J Korean Med Sci"},{"key":"3720_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1186\/cc2183","volume":"7","author":"A Trampuz","year":"2003","unstructured":"Trampuz A, Jereb M, Muzlovic I, Prabhu RM. Clinical review: severe malaria. Crit Care. 2003;7:315\u201323.","journal-title":"Crit Care"},{"key":"3720_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/femsre\/fuw037","volume":"41","author":"CJ Woodrow","year":"2017","unstructured":"Woodrow CJ, White NJ. The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiol Rev. 2017;41:34\u201348.","journal-title":"FEMS Microbiol Rev"},{"key":"3720_CR42","first-page":"257","volume":"40","author":"J Commey","year":"1994","unstructured":"Commey J, Quarm-Goka B, Agyepong I. Persistent fever in severe malaria in children. Cent Afr J Med. 1994;40:257\u201360.","journal-title":"Cent Afr J Med"},{"key":"3720_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/parasite\/2018021","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau JM, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.","journal-title":"Parasite"},{"key":"3720_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"3720_CR45","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3720_CR46","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1056\/NEJMc1410735","volume":"371","author":"M Hawkes","year":"2014","unstructured":"Hawkes M, Conroy AL, Kain KC. Spread of artemisinin resistance in malaria. N Engl J Med. 2014;371:1944\u20135.","journal-title":"N Engl J Med"},{"key":"3720_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMc1705789","volume":"377","author":"C Rasmussen","year":"2017","unstructured":"Rasmussen C, Nyunt MM, Ringwald P. Artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;377:305\u20136.","journal-title":"N Engl J Med"},{"key":"3720_CR48","doi-asserted-by":"publisher","first-page":"e1001564","DOI":"10.1371\/journal.pmed.1001564","volume":"10","author":"WorldWide Antimalarial Resistance Network DPSG","year":"2013","unstructured":"WorldWide Antimalarial Resistance Network DPSG. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10:e1001564.","journal-title":"PLoS Med"},{"key":"3720_CR49","doi-asserted-by":"publisher","first-page":"l4807","DOI":"10.1136\/bmj.l4807","volume":"366","author":"E Mahase","year":"2019","unstructured":"Mahase E. Malaria drugs left ineffective by spread of multidrug resistant parasites in southeast Asia. BMJ. 2019;366:l4807.","journal-title":"BMJ"},{"key":"3720_CR50","unstructured":"Vietnam Ministry of Health. [Guideline for diagnosis and treatment of malaria 2009] (in Vietnamese). Hanoi, 2009. https:\/\/vanbanphapluat.co\/quyet-dinh-4605-q-c3-90-byt-huong-dan-chan-doan-va-dieu-tri-sot-ret. Accessed 5 Aug 2019."},{"key":"3720_CR51","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12936-016-1535-8","volume":"15","author":"JB Roseau","year":"2016","unstructured":"Roseau JB, Pradines B, Paleiron N, Vedy S, Madamet M, Simon F, et al. Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient. Malar J. 2016;15:479.","journal-title":"Malar J"},{"key":"3720_CR52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1475-2875-13-138","volume":"13","author":"EM Hodel","year":"2014","unstructured":"Hodel EM, Kay K, Hayes DJ, Terlouw DJ, Hastings IM. Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling. Malar J. 2014;13:138.","journal-title":"Malar J"},{"key":"3720_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1128\/AAC.00878-07","volume":"52","author":"BR Moore","year":"2008","unstructured":"Moore BR, Batty KT, Andrzejewski C, Jago JD, Page-Sharp M, Ilett KF. Pharmacokinetics and pharmacodynamics of piperaquine in a murine malaria model. Antimicrob Agents Chemother. 2008;52:306\u201311.","journal-title":"Antimicrob Agents Chemother"},{"key":"3720_CR54","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2011.254","volume":"91","author":"J Tarning","year":"2012","unstructured":"Tarning J, Zongo I, Som\u00e9 FA, Rouamba N, Parikh S, Rosenthal PJ, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther. 2012;91:497\u2013505.","journal-title":"Clin Pharmacol Ther"},{"key":"3720_CR55","doi-asserted-by":"publisher","first-page":"e1002212","DOI":"10.1371\/journal.pmed.1002212","volume":"14","author":"RM Hoglund","year":"2017","unstructured":"Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14:e1002212.","journal-title":"PLoS Med"},{"key":"3720_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2875-9-53","volume":"9","author":"A Sowunmi","year":"2010","unstructured":"Sowunmi A, Adewoye EO, Gbotsho GO, Happi CT, Sijuade A, Folarin OA, et al. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J. 2010;9:53.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03720-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03720-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:14:50Z","timestamp":1675232090000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03720-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03720-3","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the HTD\u2019s Ethics Committee (approval number 65\/QD-BVBND) and the Human Research Ethics Committee at UNSW Australia (Approval Number HC180340).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}